進階篩選

Technical category
    • Modular Polymeric Nanoshells for Precision AntiviralAnticancer Vaccination

      Bio-tech & New Drugs FutureTech Modular Polymeric Nanoshells for Precision AntiviralAnticancer Vaccination

      Effectively inducing cytotoxic T cell expansion has been a critical challenge in vaccine development. To address this challenge, an entirely biodegradable polymeric nanoshell was invented to couple antigensadjuvants for safepotent immune potentiation. The invention has been adopted for precision anticancer vaccine, broadly reactive influenza vaccine,an effective vaccine MERS-CoV.
    • 抗癌小分子新藥之臨床前開發與精準治療策略

      FutureTech 抗癌小分子新藥之臨床前開發與精準治療策略

      MPT0G211 is a highly selective HDAC6 inhibitor, with comprehensive IP protection. MPT0G211 is mainly focused on multiple myelomabrain tumor indications. For IND package, we have completed CMC in drug substance, CMC in drug product, ADME,most preclinical toxicology studies, only the 28-days repeated dose toxicology study in dog is left. Once the 28-day repeated dose toxicology study in dog is completed, the IND package will be filed in the United StatesTaiwan in Q2 2022.
    • 個人化精準腫瘤治療顧問-腦轉移腫瘤

      FutureTech 個人化精準腫瘤治療顧問-腦轉移腫瘤

      PCA-BM includes two models: “Automatic BMs Segmentation AI Model”" Distant Brain Failure Prediction Model". The former one uses C2FNAS (coarse to fine network architecture search) to detect the location, size,number of brain metastases. The latter uses radiomics to extract numerous radiographic featuresemploys machine learning methods such as XGBoost to establish a prognostic model of brain metastases. PCA-BM provides more precision treatment decisions for patientsimproves personalizedaccurate overall stereotactic radiosurgery planning.
    • BPR1R系列:新穎集落刺激因子1受體抑制劑作為癌症免疫調節劑

      FutureTech BPR1R系列:新穎集落刺激因子1受體抑制劑作為癌症免疫調節劑

      We have identified a series of BPR1R compounds as highly selective CSF1R inhibitors with excellent oral bioavailability. In vivo, oral administration of BPR1R compounds delayed murine colon tumor growthreversed the immunosuppressive TME with increased M1/M2 ratio. The US & PCT patent application including more than 160 novel compounds was filed in April 20, 2020. Several potential compounds are undergoing candidate assessment for further preclinical studies.
    • 人工智慧輔助胰臟癌偵測工具-PANCREASaver

      FutureTech 人工智慧輔助胰臟癌偵測工具-PANCREASaver

      PANCREASaver contains a “PC automatic segmentation model” (image segmentation)a “PC analysis AI model” (image classification) that can read the DICOM format of postcontrast CT images directly for the automatic analysis process. After conducting prep-processing with image processing algorithms, C2FNAS is employed to illustrate the tumor position prior to the diagnosis conducted by CNN. The results can be provided to the physician for diagnostic reference so as to reduce early omissionsincrease the detection rate of pancreatic cancer.
    • IoT of food allergen detector system

      Medical Devices FutureTech IoT of food allergen detector system

      Our IoT of food allergen detection system has high sensitivityspecificity by magnetic nano-beads with advanced material coating. This advanced material successful inhibit biofouling in biosensor system. Other than this, Our system combine nanotechnology, biotechnology, IoTAI model. Device is small any easily carry to anywhere.
    • Super AI HPC System

      AI & IOT Application FutureTech Super AI HPC System

      Super fast terapixel server allows multiple users to viewanalyze gigapixelterapixel images with mobile devices, such as iPhones, iPads, Android mobiles,laptops at the same time. Users could annotateanalyze the data using built-in tools such as 3d effect, color deconvolution, color quantification, nuclei/object detection, lengtharea measurement,quantitative reporting system.